MedPage Today -- The investigational drug lasofoxifene (Fablyn), a selective estrogen receptor modulator under evaluation for osteoporosis treatment, reduced the risk of vertebral and other fractures as well as certain cardiovascular events in postmenopausal women, researchers said.
